LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc.
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA Overall market growth is stable and unmet needs remain Efficacy is key reason to prescribe High switch and discontinuation rates Strong clinical profile and competitive LATUDA label Inclusion of olanzapine arm in efficacy and weight data sections (as an active control to assess assay sensitivity) 4 positive efficacy studies Two dose options, once-daily 2,000+ safety database No QTc warning 336 dedicated and experienced Sales Force Majority have previously sold at least 1 other atypical antipsychotic Customer-centric commercial organization Focus on engaging psychiatrists through multimodal approach Competitive pricing and reimbursement strategies 1
Atypical Antipsychotic Market Growing at 3% $15.8BN Market Growth in the Atypical Antipsychotic Category Is Being Driven by Use in Bipolar Disorder and Depression 60,000 TRx (000s) 50,000 40,000 30,000 20,000 49MM 50MM 47MM 2,372 2,373 2,120 5,847 6,644 6,522 9,121 8,647 8,373 14,169 14,735 15,045 DX Anxiety Depression All others Schizophrenia CAGR 6% 6% -4% 3% 10,000 15,324 16,237 17,202 Bipolar Disorder Market 6% 3% 0 MAT Nov 2008 MAT Nov 2009 MAT Nov 2010 Bipolar Disorder Schizophrenia All others Depression Anxiety Source: Derived from IMS NPA Data, and SDI PDDA 2
Monthly Antipsychotic Market TRx Share Trend Established Market 40% 35% 30% Seroquel TRx Share 25% 20% 15% 10% 5% Risperidone Abilify Zyprexa Geodon Seroquel XR Saphris 0% D J F M A M J J A S O N D J F M A M J J A S O N D J F M A M J J A S O N 2007 2008 2009 2010 Fanapt Source: IMS NPA. The Atypical antipsychotic market is defined as ANTIPSYCHOTICS, OTHERS (USC 64190), excluding Haldol, Loxapin, Moban, Navane, Orap, and Thiothixene, etc. 3
Psychiatrists Need New Treatments that Provide a Combination of Strong Efficacy and Tolerability Efficacy Effective in Treating Positive Symptoms Effectively controls agitation/aggression 53 80 Safety Safe for Long-Term Therapy 49 Tolerability Well Tolerated 66 Good patient compliance 49 Does Not Cause Significant Weight Gain Effective in Treating Negative Symptoms Low Incidence of Extrapyramidal Side Effects 39 39 37 0 25 50 75 100 Percent of Psychiatrists Higher Importance Medium Importance Source: GfK, 2009 Schizophrenia Physician Study 4
No Single Preferred Agent for Treatment of Schizophrenia All Uses MAT Sept 2010 Schizophrenia Uses MAT Sept 2010 Invega Sustenna Risperdal Risperdal 0.2% FANAPT Consta 0.5% Invega 0.1% 0.9% Saphris 1.8% Clozapine 0.3% 2.6% Seroquel XR Geodon 6.7% 5.4% Seroquel 29.5% Zyprexa 10.3% Abilify 19.8% Risperidone 22.1% Seroquel XR 3.8% Risperdal Consta 4.1% Geodon 8.4% Clozapine 10.0% Invega 3.2% Abilify 13.5% Invega Sustenna 0.8% Zyprexa 16.5% Saphris 0.4% Fanapt 0.2% Risperidone 21.2% Seroquel 18.0% Source: Wolters Kluwer Source Lx Based on Market Research 5
High Discontinuation Rates Create Opportunity for LATUDA CATIE Reinforced Need for New Treatment Options 74% of patients discontinued the study medication before 18 months Patients dissatisfied with current options Continue to experience breakthrough symptoms Discontinue due to adverse events, lack of efficacy Likely to have tried multiple medications Two drugs, olanzapine and clozapine, appear to be more effective than other agents. However, both drugs induce a significantly greater number of serious side effects. Even the most feared side effect tardive dyskinesia, seems less troubling than potentially fatal metabolic problems. Robert Freedman, MD, NEJM 6
Leverage Strong Clinical Profile and Positive Label Opportunity to improve value proposition vs. current atypical antipsychotics Once-daily with food The recommended starting dose is the therapeutic dose 40 mg LATUDA offers proven efficacy with positive cardiometabolic profile No QTc warning Differentiate from current atypical antipsychotics that offer partial efficacy/response 4 positive efficacy studies included in label Efficacy confirmed for both doses in 2 studies each 7
Psychiatrists Are Key Driver for Launch A large and stable market with ~2 million patients with Schizophrenia in the US Our current target audience ~22,000 psychiatrists 336 Sales Force will cover target audience and will be able to attain competitive share of voice by focusing on these specialists Schizophrenia Treatment by Specialty Neuro 0.5% PCP & Others, 3% Psych, 97% Source: SDI PDDA 8
Leverage Dedicated and Experienced Sales Force Ready to Deliver on the Potential of LATUDA Sales force: 336 Hospital sales force: 70 Extensive experience selling in the atypical antipsychotic arena Dedicated and qualified Area Medical Specialists team Managed care and Government Affairs team with strong category knowledge 9
Sunovion Is Uniquely Positioned to Deliver Strong Performance for LATUDA Unsatisfied physician and patient population as evidenced by high switch rates creates opportunity for LATUDA LATUDA has a strong clinical profile and competitive label Dedicated and experienced Sales Force ready to compete Focused on key access issues to ensure success 10
Disclaimer Regarding Forward-looking Statements The statements made in this presentation material are forward-looking statements based on management s assumptions and beliefs in light of information available up to the day of announcement, and involve both known and unknown risks and uncertainties. Actual financial results may differ materially from those presented in this document, being dependent on a number of factors. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. 11